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ABSTRACT
Background. Extranodal spread (ENS) is an established
adverse prognostic factor in metastatic cutaneous squa-
mous cell carcinoma (cSCC); however, the clinical
signiﬁcance of soft tissue metastases (STM) is unknown.
The aim of this study was to evaluate the prognosis of
patients with STM from head and neck cSCC, and to
compare this with that of node metastases with and without
ENS.
Methods. Patients with cSCC metastatic to the parotid
and/or neck treated by primary surgical resection between
1987 and 2007 were included. Metastatic nodes[3c mi n
size were an exclusion criterion. A Cox proportional hazard
model was used to determine the effect of STM adjusting
for other relevant prognostic factors.
Results. The population included 164 patients with a
median follow-up of 26 months. There were 8 distant and
37 regional recurrences. There were 22 were cancer-spe-
ciﬁc deaths, and 29 patients died. STM was a signiﬁcant
predictor of reduced overall (hazard ratio 3.3; 95% conﬁ-
dence interval 1.6–6.4; P = 0.001) and disease-free
survival (hazard ratio 2.4; 95% conﬁdence interval 1.4–4.1;
P = 0.001) when compared to patients with node disease
with or without ENS. After adjusting for covariates, STM
and number of involved nodes were signiﬁcant independent
predictors of overall and disease-free survival.
Conclusions. In metastatic cSCC of the head and neck, the
presence of STM is an independent predictor of reduced
survival and is associated with a greater adverse effect than
ENS alone.
In countries with large white populations and high
ambient solar exposure such as Australia and New Zealand,
cutaneous squamous cell carcinoma (cSCC) is a major
public health problem.
1 Most cases of cSCC arise in the
head and neck, and regional metastases to parotid and/or
cervical lymph nodes are thought to occur in approxi-
mately 5% of patients, decreasing 5-year survival rates to
46–70%.
2–9
Although extension of metastatic squamous cell carci-
noma (SCC) beyond the lymph node capsule (extracapsular
spread or extranodal spread, ENS) is a well-established
adverse prognostic factor, there is no published evidence
regarding the clinical signiﬁcance of soft tissue metastases
(STM) in cSCC.
6,10 STM are deﬁned as free soft tissue
tumor deposits lacking continuity with the primary tumor
and without discernible associated lymph node tissue.
It remains unclear whether these are true extranodal
metastases or whether they represent lymph nodes replaced
by tumor to such an extent that the underlying node is
unrecognizable.
11 In the latter case, STM may represent an
advanced stage of node disease beyond ENS, and if this is
the case, larger tumor size and reduced locoregional con-
trol would be expected. This notion is supported by the
known correlation between the size of involved lymph
nodes and the presence of ENS.
12 Several studies of
mucosal head and neck SCC have demonstrated an asso-
ciation between STM and unfavorable outcomes,
comparable to the presence of ENS.
11–16
 The Author(s) 2011. This article is published with open access
at Springerlink.com
First Received: 26 December 2010;
Published Online: 9 August 2011
J. R. Clark, MBBS FRACS
e-mail: jcjc@tpg.com.au
Ann Surg Oncol (2012) 19:274–279
DOI 10.1245/s10434-011-1986-7It was unclear from our clinical experience whether
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tumor biology. The goal of the current study was to eval-
uate the prognostic signiﬁcance of STM in head and neck




Head and Neck Cancer Institute, Royal Prince Alfred Hos-
pital, Sydney, Australia, were recorded prospectively on a
computerized database since 1987. The database contains
information on patient demographics, clinical and patho-
logic staging, treatment details, histopathologic features,
duration of follow-up, and status at last visit. All patients
with cSCC metastatic to the parotid and/or neck treated by
primarysurgicalresectionwithcurativeintentbetween1987
and 2007 were identiﬁed. The pathology details recorded in
the database were cross-checked with the original pathology
reports and the database was updated where necessary.
Slides of tumors from all selected patients were reexamined
by a pathologist experienced in the examination of head and
neck tumors (R.M.).ENSwas deﬁned asextensionoflymph
node metastases of SCC beyond the nodal capsule, and
STMsweredeﬁnedasfreesofttissuetumordepositslacking
continuity with the primary tumor and without discernible
associated lymph node tissue. The presence, size, and
number of STM were measured and added to the existing
database. To exclude the effect of bulky tumors, only
patients with metastatic nodes B3 cm in size were included.
Data were collated and ﬁltered by Microsoft Excel, and
statistical analysis was performed by SPSS version 16.0
(SPSS, Chicago, IL). Categorical data were analyzed by
chi-square test or Fisher’s exact test, normally distributed
continuous data by t-test, and nonparametric data by
Kruskal–Wallis test where appropriate. All statistics were
two sided, and a P value of \0.05 was considered statis-
tically signiﬁcant. Overall survival was calculated from the
date of surgery to date of death or last follow-up. Disease-
free survival was calculated from the date of surgery to
date of last follow-up including date of death from any
cause if there were no recurrence or date of ﬁrst disease
recurrence. Differences in survival were determined by
univariate Cox regression analysis, and survival curves
were generated by the Kaplan–Meier method. A Cox pro-
portional hazard model was used to adjust for the effect of
other statistically signiﬁcant covariates and potential con-
founders, including postoperative radiotherapy and the
number of tumor deposits, by means of purposeful selec-
tion of covariates to develop a ﬁnal multivariable model




The study population included 164 patients, 142 men
(86.6%) and 22 women (13.4%), with a median age at
surgery of 73 years (range 25–98 years) and a median
follow-up period of 26 months. Surgical treatment con-
sisted of parotidectomy with neck dissection in 129
patients (78.7%), neck dissection alone in 14 (8.5%), and
parotidectomy alone in 21 (12.8%). Adjuvant radiotherapy,
at a median dose of 54 Gy (range 32–66 Gy), was
administered to 131 patients (79.9%).
Pathology of Metastatic Disease
The median number of either positive nodes or meta-
static deposits was 1, while the mean number was 3.7
(range 1–68). Most patients (104, 63.4%) had only one
affected node or STM. The margins of excision were clear
in 83 patients (50.6%), involved in 27 patients (16.5%),
and close (\5 mm) in 38 patients (23.2%), and there was
no information on margin status in 16 patients (9.8%).
Fifty-eight patients (35.4%) had node metastases without
ENS or STM, 51 (31.1%) had ENS and STM, 33 (20.1%)
had ENS alone, and 22 (13.4%) had STM alone (Fig. 1).
The median size of the largest node or STM was 1.8 cm.
The mean diameter of involved nodes (in the selected
group of patients with tumors B3 cm) without ENS, nodes
with ENS, and STMs was 1.9 cm (range 0.5–3.0 cm),
1.7 cm (range 0.6–2.5 cm), and 2.1 cm (range 1.0–3.0
cm), respectively (P = 0.085; Kruskal–Wallis test). Sev-
enty-one patients (43%) had nodes\1.5 cm.
During the follow up there were eight distant and 37
regional recurrences. Twenty-nine patients died; there were
FIG. 1 STM of cutaneous SCC
Carcinoma with Regional Metastases 27522 cancer-speciﬁc deaths. STM was a signiﬁcant predictor
of reduced overall [hazard ratio (HR) 3.3; 95% conﬁdence
interval (CI) 1.6–6.4; P = 0.001] and disease-free survival
(HR, 2.4; 95% CI 1.4–4.1; P = 0.001) when compared to
patients with node disease with or without ENS (Fig. 2).
The presence of ENS was also a signiﬁcant predictor of
survival when compared to patients without ENS or soft
tissue deposits. Other signiﬁcant predictors of survival on
univariate analysis are summarized in Table 1. After
adjusting for other covariates, STM and number of
involved nodes (or tumor deposits) were signiﬁcant inde-
pendent predictors of overall and disease-free survival, but
ENS was not (Table 2).
To compare the prognostic impact of STM and ENS, the
study population was divided into four groups: STM and
ENS; STM alone; ENS alone; and node disease without
ENS or STM. The adjusted Cox regression curves in Fig. 3
show that the worst outcomes were associated with STM
with or without associated ENS, while node disease with-
out STM or ENS was associated with the most favorable
outcomes, and ENS alone had an intermediate prognosis.
When the subset of patients with STM alone (n = 22)
were compared with those with ENS alone (n = 33),
patients with STM alone had signiﬁcantly reduced overall
survival (HR 4.1; 95% CI 1.0–16.8; P = 0.048) when
compared to those with ENS alone after adjusting for the
effect of age and number of lymph nodes (Fig. 4).
DISCUSSION
The results of the present study suggest that the presence
of STMs is associated with a worse prognosis than the
presence of node metastases (with or without ENS). We
were unable to conﬁrm that ENS in node metastases B3c m
in size is associated with reduced survival after adjusting
for the effect of STM and number of nodes involved.
However, it is likely that the study is insufﬁciently powered
to detect a statistically signiﬁcant difference because the
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FIG. 2 Kaplan–Meier curves
according to the presence or
absence of STM for (a) overall
survival and (b) disease-free
survival
TABLE 1 Univariate survival analysis
Variable HR 95% CI P value
Overall survival
Age (continuous) 1.04 1.00–1.08 0.031
Involved margin 1.62 0.73–3.56 0.233
Maximal lesion size
Size (continuous) 1.02 0.96–1.09 0.484
[1.5 versus B1.5 cm 1.28 0.56–2.92 0.565
No. of nodes
2–3 nodes versus 1 node 1.03 0.38–2.83 0.949
C4 nodes versus 1 node 5.13 2.35–11.20 \0.001
STM 3.25 1.63–6.49 0.001
ENS
a 2.59 1.30–5.16 0.007
Adjuvant radiotherapy
a 0.72 0.33–1.57 0.405
Disease-free survival
Age 1.02 0.99–1.04 0.220
Involved margin 2.18 1.20–3.96 0.010
Maximal lesion size
Size (continuous) 1.02 0.98–1.07 0.390
[1.5 versus B1.5 cm 1.40 0.73–2.67 0.310
No. of nodes
2–3 nodes versus 1 node 1.73 0.84–3.57 0.135
C4 nodes versus 1 node 4.94 2.51–9.73 \0.001
STM
a 2.42 1.42–4.14 0.001
ENS
a 2.01 1.17–3.45 0.012
Adjuvant radiotherapy 0.79 0.42–1.50 0.471
a Different reference categories for STM and ENS mean hazards are
not comparable
276 W. Kelder et al.STM (type II error). This lends support to the argument that
STMs, rather than representing lymph nodes completely
replaced by tumor, may instead represent a distinct bio-
logic entity (namely deposits of tumor in soft tissue, not
associated with lymph nodes).
Because number and size of tumor deposits are impor-
tant prognostic factors and size of the tumor is related to
the presence of ENS and STM, we tried to exclude the
effect of bulky tumors by only selecting patients with
tumors up to 3 cm as supported by the N1S3 and current
tumor, node, metastasis staging systems.
10,12,18 In this
subgroup, the presence of STM was a statistically signiﬁ-
cant adverse prognostic factor, and the effect was even
more pronounced in patients with both STM and ENS.
A limitation of this study is that primary tumor infor-
mation is not evaluated. Other factors that could confound
the effect of STM include perineural invasion, lympho-
vascular invasion, depth of invasion, tumor grade, and
immune status of the patient.
3,7 Many of these factors were
adopted in the 7th edition of the American Joint Committee
on Cancer/International Union Against Cancer staging
system for cSCC. The prognostic signiﬁcance of primary
tumor factors in patients with node metastases is unknown.
Patients in this study were only referred with node
metastases, primary tumor data was often unavailable and
many patients have either no identiﬁable primary or mul-
tiple potential primaries.
Extranodal spread and soft tissue metastases are com-
mon ﬁndings in patients with metastatic cutaneous and
mucosal SCC, one or the other being present in most
patients.
6,
11–16 Generally, the distinction has been ignored
by pathologists and clinicians and both have been grouped
together. Studies in mucosal SCC have shown that the
presence of both STM and/or ENS is related to reduced
survival, but it is not clear from those studies whether STM
and ENS are identical.
11–16 Partly this is because the term
‘‘soft tissue deposit or metastasis’’ is used rather impre-
cisely and may include direct extension of tumor cells from
the primary site or even ENS of tumor from the lymph
node into the soft tissues of the neck. In an attempt to be
more speciﬁc we deﬁned STM as ‘‘free soft tissue tumor
deposits lacking continuity with the primary tumor and
without discernible associated lymph node tissue.’’ In
melanoma, ‘‘microscopic satellitosis’’ represents a parallel
adverse prognostic factor that has been more extensively
studied and strictly deﬁned as ‘‘any discontinuous nest of
metastatic cells more than 0.05 mm in diameter that are
clearly separated by normal dermis from the main invasive
component of melanoma by a distance of at least
0.3 mm.’’
19 Despite the similarity, we believe that these are
different biologic entities as STM mainly occur in node
basins rather than as dermal deposits within close prox-
imity to the primary tumor. Regardless, a strict deﬁnition
such as that adopted for microscopic satellitosis would
enable reliable and reproducible estimates of STM’s
prognostic signiﬁcance in future studies.
20–22
STM could occur via spread of tumor cells through
lymphatic channels draining the primary tumor or through
perineural or vascular routes. Tumor cells that spread
through lymphatics eventually reach lymph nodes, where
they will either be contained by the local immune system
or will overcome the local host defense and may eventually
replace the whole lymph node with tumor. It has been
demonstrated in animal models that some tumor cells
escape the lymphatics or travel through small vessels and
end up as free tumor deposits in the soft tissues.
23 Tumors
escaping lymphatic channels may possess cellular proper-
ties that promote growth and dissemination and may avoid
some of the immune regulation that normally occurs in
lymph nodes, whereas tumors with direct vascular invasion
may be more prone to distant spread. The real explanation
is likely to be complicated and multifactorial, and merits
further study.
In this series, the predominant site of recurrence was
within the parotid and neck suggesting that the focus of
treatment should remain on optimizing locoregional con-
trol. There is good evidence that combined modality
treatment with surgery and adjuvant radiotherapy improves
locoregional control and survival in head and neck
cSCC.
5,24–26 However, radiotherapy is associated with
marked acute and long-term toxicity, and a recent multi-
center study involving our institution suggests there is a
low-risk group of patients with N1S3 stage I disease (single
lymph node B3 cm) and no ENS or STM that may be
suitable for treatment with surgery alone.
10,27,28 Con-
versely, the results of the Trans-Tasman Radiation
Oncology Group trial (Postoperative Skin Trial 05.01;
http://www.trog.com.au/) are awaited to determine whether
TABLE 2 Final multivariable survival analysis models
Variable HR 95% CI P value
Overall survival
Age (continuous) 1.03 1.00–1.07 0.072
No. of nodes 2.34 1.49–3.66 \0.001
STM 2.91 1.44–5.88 0.003
Adjuvant radiotherapy 0.63 0.28–1.40 0.256
ENS 1.54 0.72–3.29 0.263
Disease-free survival
Age 1.01 0.98–1.04 0.487
Margin 0.96 0.49–1.86 0.899
No. of nodes 2.31 1.61–3.32 \0.001
STM 2.35 1.35–4.07 0.002
Adjuvant radiotherapy 0.75 0.39–1.44 0.385
ENS 1.30 (0.71–2.38) 0.395
Carcinoma with Regional Metastases 277intensiﬁcation of treatment regimens with adjuvant che-
moradiation may be beneﬁcial for high-risk metastatic
cSCC of the head and neck. Hence, accurate prognostic
information remains critical to making decisions regarding
deescalation or intensiﬁcation of adjuvant therapy.
Soft tissue metastases have a comparable adverse effect
on survival to multiple lymph node metastases. Therefore,
adjuvant radiotherapy should be administered to all
patients with STM, even if the metastasis is a small single
deposit. We are cautious about making recommendations
for patients with ENS, despite being unable to demonstrate
a marked effect. Therefore, conventional multimodal
therapy should be considered standard on the basis of
evidence from multiple studies which have shown ENS to
be an adverse prognostic factor, even though they are likely
to have grouped ENS and STM together.
6,7,10
The pathologic examination and reporting of parotid and
neck dissection specimens is paramount to obtaining
reliable prognostic information on which to base treatment
decisions. It is essential that examination of all tumor
deposits and lymph nodes (including the smallest nodes) is
performed for the presence of ENS and STM, along with
measurement of the size and number of metastases.
10 This
approach has also been recommended in other solid
tumors, for example colorectal cancers, in which the
majority of metastases are found in lymph nodes that are
smaller than 5 mm in size, and even small metastatic tumor
deposits have a negative prognostic impact.
29–31 As in
many solid tumors, a low number of examined nodes
probably represents understaging, and is associated with
poorer prognosis.
31 Clearly, adequate staging requires not
only a meticulous surgical technique but also a detailed
pathologic evaluation.
In conclusion, in metastatic cSCC of the head and neck,
the presence of STM (with or without associated ENS) is a
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FIG. 3 Cox proportional
hazard regression comparing
(a) overall survival and
(b) disease-free survival,
according to presence of ENS
and STM versus STM alone
versus ENS alone versus node
disease without ENS or STM;
adjusted by age, number of
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FIG. 4 Cox proportional
hazard regression comparing
(a) overall survival and
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alone versus ENS alone;
adjusted by age and number of
involved nodes
278 W. Kelder et al.survival and is associated with more unfavorable outcomes
than the presence of ENS alone. Further work is required to
determine the biologic mechanisms underlying this ﬁnding.
Similar to the guidelines in melanoma, pathology reports of
head and neck cSCC should include the number and size of
affected nodes,the presence ofENS,aswell asthe presence,
number, and size of STMs. The threshold for aggressive
multimodaltreatmentshouldbelowinthepresenceofSTM.
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